CureVac N.V (NASDAQ: CVAC) kicked off on Monday, down -6.33% from the previous trading day, before settling in for the closing price of $3.79. Over the past 52 weeks, CVAC has traded in a range of $2.21-$5.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 61.13% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 167.52%. With a float of $93.63 million, this company’s outstanding shares have now reached $224.34 million.
In an organization with 1172 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 69.76%, operating margin of 24.15%, and the pretax margin is 26.75%.
CureVac N.V (CVAC) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of CureVac N.V is 58.26%, while institutional ownership is 5.14%. The most recent insider transaction that took place on Jan 07 ’25, was worth 88,019. Before that another transaction happened on Jan 07 ’25, when Company’s affiliate proposed sale 51,523 for $4.93, making the entire transaction worth $254,219.
CureVac N.V (CVAC) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 167.52% per share during the next fiscal year.
CureVac N.V (NASDAQ: CVAC) Trading Performance Indicators
Take a look at CureVac N.V’s (CVAC) current performance indicators. Last quarter, stock had a quick ratio of 6.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.34. Likewise, its price to free cash flow for the trailing twelve months is 7.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.54, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of CureVac N.V (CVAC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.56 million. That was inferior than the volume of 1.17 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.95%. Additionally, its Average True Range was 0.27.
During the past 100 days, CureVac N.V’s (CVAC) raw stochastic average was set at 44.87%, which indicates a significant increase from 4.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.66% in the past 14 days, which was lower than the 65.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.39, while its 200-day Moving Average is $3.25. However, in the short run, CureVac N.V’s stock first resistance to watch stands at $3.66. Second resistance stands at $3.76. The third major resistance level sits at $3.83. If the price goes on to break the first support level at $3.48, it is likely to go to the next support level at $3.41. The third support level lies at $3.30 if the price breaches the second support level.
CureVac N.V (NASDAQ: CVAC) Key Stats
The company with the Market Capitalisation of 796.29 million has total of 223,880K Shares Outstanding. Its annual sales at the moment are 58,180 K in contrast with the sum of -281,580 K annual income. Company’s last quarter sales were recorded 543,090 K and last quarter income was 371,710 K.
